We’ve recently updated our valuation analysis.

Envista Holdings Valuation

Is NVST undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NVST?

Other financial metrics that can be useful for relative valuation.

NVST key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.8x
Enterprise Value/EBITDA14.3x
PEG Ratio1.4x

Price to Earnings Ratio vs Peers

How does NVST's PE Ratio compare to its peers?

The above table shows the PE ratio for NVST vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average35.3x
IART Integra LifeSciences Holdings
25.9x9.7%US$4.5b
GMED Globus Medical
45.8x11.6%US$7.1b
TFX Teleflex
25.7x12.1%US$10.6b
MASI Masimo
44x23.7%US$7.5b
NVST Envista Holdings
29.1x20.3%US$6.0b

Price-To-Earnings vs Peers: NVST is good value based on its Price-To-Earnings Ratio (29.1x) compared to the peer average (35.3x).


Price to Earnings Ratio vs Industry

How does NVST's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.2%
n/an/an/a

Price-To-Earnings vs Industry: NVST is good value based on its Price-To-Earnings Ratio (29.1x) compared to the US Medical Equipment industry average (32.7x)


Price to Earnings Ratio vs Fair Ratio

What is NVST's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NVST PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.1x
Fair PE Ratio30.1x

Price-To-Earnings vs Fair Ratio: NVST is good value based on its Price-To-Earnings Ratio (29.1x) compared to the estimated Fair Price-To-Earnings Ratio (30.1x).


Share Price vs Fair Value

What is the Fair Price of NVST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NVST ($36.99) is trading below our estimate of fair value ($55.69)

Significantly Below Fair Value: NVST is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NVST forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$36.99
US$43.89
+18.7%
6.9%US$48.00US$38.00n/a9
Nov ’23US$34.17
US$45.67
+33.6%
8.3%US$50.00US$38.00n/a9
Oct ’23US$32.81
US$48.22
+47.0%
6.2%US$54.00US$44.00n/a9
Sep ’23US$36.38
US$48.22
+32.6%
6.2%US$54.00US$44.00n/a9
Aug ’23US$41.07
US$50.00
+21.7%
10.3%US$60.00US$43.00n/a9
Jul ’23US$39.14
US$54.44
+39.1%
9.0%US$61.00US$46.00n/a9
Jun ’23US$42.01
US$55.89
+33.0%
6.2%US$61.00US$49.00n/a9
May ’23US$39.62
US$55.78
+40.8%
5.7%US$61.00US$50.00n/a9
Apr ’23US$48.10
US$54.67
+13.7%
5.6%US$61.00US$50.00n/a9
Mar ’23US$47.63
US$54.11
+13.6%
4.0%US$58.00US$50.00n/a9
Feb ’23US$43.40
US$52.00
+19.8%
5.1%US$55.00US$47.00n/a9
Jan ’23US$45.06
US$48.83
+8.4%
7.4%US$53.00US$42.00n/a6
Dec ’22US$38.15
US$49.20
+29.0%
7.9%US$53.00US$42.00n/a5
Nov ’22US$40.12
US$50.20
+25.1%
7.3%US$55.00US$42.00US$34.1710
Oct ’22US$42.78
US$51.10
+19.4%
5.8%US$55.00US$46.00US$32.8110
Sep ’22US$42.81
US$51.73
+20.8%
6.7%US$58.00US$46.00US$36.3811
Aug ’22US$43.08
US$50.55
+17.3%
6.5%US$57.00US$45.00US$41.0711
Jul ’22US$43.77
US$50.55
+15.5%
6.5%US$57.00US$45.00US$39.1411
Jun ’22US$42.92
US$50.55
+17.8%
6.5%US$57.00US$45.00US$42.0111
May ’22US$43.28
US$45.73
+5.7%
7.5%US$53.00US$41.00US$39.6211
Apr ’22US$40.83
US$44.91
+10.0%
7.1%US$53.00US$41.00US$48.1011
Mar ’22US$39.47
US$44.73
+13.3%
7.1%US$53.00US$41.00US$47.6311
Feb ’22US$36.02
US$37.64
+4.5%
13.5%US$47.00US$28.00US$43.4011
Jan ’22US$33.73
US$32.91
-2.4%
7.9%US$37.00US$28.00US$45.0611
Dec ’21US$30.07
US$31.09
+3.4%
6.8%US$35.00US$28.00US$38.1511
Nov ’21US$26.42
US$29.64
+12.2%
12.1%US$35.00US$20.00US$40.1211

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies